JERUSALEM (Reuters) - Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukemia and other blood cancers met all safety and efficacy goals.
Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its treatment, currently called BL-8040, needed just one.
00:27 Trump warns of ‘retribution’ if companies move jobs out of U.S10
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff13
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle14
13:37 GoPro to cut about 15 percent of workforce13